THX Pharma Names Julien Veys as Deputy CEO

THX Pharma (Theranexus), a pharmaceutical company focused on rare neurological diseases, has announced the appointment of Julien Veys as Deputy Chief Executive Officer. This move aligns with the company's strategy to enhance regulatory approval and international commercialization of its treatments.

Julien Veys, who joined THX Pharma in 2016, previously held positions including Chief Business Development Officer and Chief Operating Officer. His contributions include Theranexus' IPO on Euronext Growth in 2017 and significant licensing deals.

His industry experience spans roles at Trophos, where he secured €17 million in R&D funding and aided in its acquisition by Roche. Julien holds a science degree from Aix-Marseille University and an MBA from HEC Paris.